These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23414196

  • 1. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
    Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, Derosa G.
    Expert Opin Pharmacother; 2013 Mar; 14(4):371-84. PubMed ID: 23414196
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A.
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.
    Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH.
    Diabetologia; 2010 Aug; 53(8):1576-80. PubMed ID: 20480132
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR, Sun NL, Yang K, Hu J, Xu G, Hong H, Wang R, Tu YM, Ritter S, Keefe D, trial investigators.
    Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL.
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [Abstract] [Full Text] [Related]

  • 14. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL.
    Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):327-33. PubMed ID: 21846154
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.
    Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH.
    Kidney Int; 2008 Jun 01; 73(12):1419-25. PubMed ID: 18337712
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.